Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Stage/Subtype:  advanced malignant mesothelioma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 28 for your search:
Start Over
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: POLARIS2015-003, NCI-2017-00005, NCT02709512
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-743, NCI-2016-01557, 2016-001859-43, NCT02899299
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Surgery, Chemotherapy, and Intensity Modulated Radiation Therapy in Treating Patients with Stage I-III Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 08-053, NCI-2016-01016, NCT00715611
Plicamycin in Treating Patients with Malignancies Involving the Lungs, Esophagus, or Pleura That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0151, NCI-2013-01534, 120151, P12961, NCT01624090
Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448
Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 14513, NCI-2014-01242, 819186, NCT02153229
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18094, NCI-2016-00002, NCT02611037
Nintedanib in Treating Patients with Malignant Pleural Mesothelioma That Is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-010, NCI-2015-01412, 1506014121, NCT02568449
Intrapleural Measles Virus Therapy in Treating Patients with Malignant Pleural Mesothelioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1023, NCI-2011-03574, 2010UC103, Mod1000260438, NCT01503177
A Study of LY3023414 in Participants With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13517, NCI-2016-01472, I6A-MC-CBBA, NCT01655225
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-001, NCI-2014-01059, NCT02071862
Genetically Modified T Cells with or without Cyclophosphamide in Treating Patients with Recurrent Mesothelin-Expressing Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 31213, NCI-2015-00392, 819826, NCT02159716
Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide in Treating Patients with Malignant Pleural Disease
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00789, NCT02414269
Interferon Gamma-1b and Nivolumab in Treating Patients with Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU-084, NCI-2016-00138, NCT02614456
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17631, NCI-2016-00280, NCT02639091
Multipeptide Vaccine S-588210 in Treating Patients with Malignant Pleural Mesothelioma that Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: IRB14-1519, NCI-2016-00090, NCT02661659
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: PM1183-A-014-15, NCI-2016-01032, NCT02611024
LMB-100 in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0127, NCI-2016-01033, P152590, NCT02798536
Start Over